EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes.
about
Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionc-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.Mig-6 controls EGFR trafficking and suppresses gliomagenesisThe constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2Role of receptor tyrosine kinases and their ligands in glioblastoma.Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cellsDifferences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Pathways driving the endocytosis of mutant and wild-type EGFR in cancer.Long-term cultured human neural stem cells undergo spontaneous transformation to tumor-initiating cells.Identification of kinases and regulatory proteins required for cell migration using a transfected cell-microarray system.Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activationDynamin2 downregulation delays EGFR endocytic trafficking and promotes EGFR signaling and invasion in hepatocellular carcinoma.Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancerEpidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosisHuntingtin-interacting protein 1 phosphorylation by receptor tyrosine kinases.Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemiaOligodendrocyte/type-2 astrocyte progenitor cells and glial-restricted precursor cells generate different tumor phenotypes in response to the identical oncogenes.Targeting EGFR resistance networks in head and neck cancer.Therapeutic targeting of EGFR in malignant gliomas.Endocytosis and signaling: cell logistics shape the eukaryotic cell plan.Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.Genetic alterations in glioma.Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies.LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.Characterization of the EGFR interactome reveals associated protein complex networks and intracellular receptor dynamics.Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma.Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation.EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.Exosomal sorting of the viral oncoprotein LMP1 is restrained by TRAF2 association at signalling endosomes.Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway.EGFR in melanoma: clinical significance and potential therapeutic target.
P2860
Q28829301-FF919E30-7BAE-4595-9AB2-0A3478C06852Q30157161-872429BA-F8A3-4B6D-A966-B804D41DBF2AQ33859568-2FD66898-29AF-44DA-AB1D-C51C2AF3CFF4Q33867510-778C494F-F201-499E-920A-8C1D9BF826CDQ33883849-40F79313-B6F2-4587-B694-9FBD274D44F4Q34043232-2886E18E-C740-4883-A74E-980BF7880802Q34286305-15E04CD9-2719-4AC8-BF62-5E9593AFA65FQ34639763-D58C37D1-B78E-4AD1-BE8A-8F6AD423D550Q34781357-5E8C2F72-DC78-48C6-AE94-B5E5365EE8A7Q35144727-6E92474A-98E1-4F0D-A355-F3063FDEB6C9Q35194120-4FF3F0C6-62A1-48E3-9348-0149CB1DD747Q35221471-6CDC5F0D-2B06-4D59-97A8-A1E3BC0755D2Q35402681-01D1C129-6F55-4E1B-9777-4B97538B4FB1Q35534349-E3533A11-B8CE-49EF-8F41-4980C86B1D3FQ35623965-7C9A4307-385D-4338-904C-2FD42DB04699Q36280796-D549E2B7-A241-4B27-B187-3EF9522265EAQ36455750-7D49BB88-5DAC-4544-B46E-F89EE0C94BD8Q37089778-7FC2C3D5-8260-45E8-A639-251EDC9E4983Q37101643-35178033-26D6-4B0E-B67D-8A6A43EAF0CAQ37122779-18DC1346-DA07-4C37-A601-FEFACF22DC00Q37201991-B7062923-9200-4EC2-80D4-8A243E20D867Q37231529-B50675F7-1B78-45B6-BB7B-6C1E2D433B1EQ37405633-F6623FCE-68A7-4B34-B019-84BF80E400DDQ37690755-A97FD618-F015-4149-9D93-531F4A716140Q37980726-54F92038-7F8A-436E-9CBF-FB90A1A9184CQ37981764-D4BE3FE9-AB09-42FC-B379-04D8B62C3F02Q38161344-41887542-EC08-4D1A-823A-AF7F6FF137F6Q38258904-C75795CC-CFFA-4151-8DCF-839C552B8B3AQ38512194-2AD0EE0E-E5EF-4127-91EF-8A6C5AA0CDB9Q38722183-AB8432D3-6C5F-4D7D-AB22-6C1381FC3718Q38750358-1F3898FC-54EE-4D57-8C31-DC6036296B47Q38912207-B9CB02F7-1C67-4FDC-BB5E-D8540781FCF2Q39108521-E3F30AC1-78AC-46AC-9DE9-5A3B8A157358Q39325255-4BADE41D-2A31-4C56-B6C3-280DD3161AEDQ39346046-6263D732-A8F3-44A5-B9DB-800DB089E534Q39350866-A6A7B3EF-E036-4735-B67F-FAC08BB0A02AQ39383476-904529BB-513F-457A-8FCB-FB90CF7C2A25Q39544175-5A6555F9-342D-4B87-AC00-6727BAFB6B76Q39584506-1007A6C1-1256-4EDB-B02C-8A3AC266B4F2Q39586032-5AB04321-1CEE-4CC7-ADCF-4B6BA63E055B
P2860
EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
EGFRvIII escapes down-regulati ...... tion and sorting to lysosomes.
@en
type
label
EGFRvIII escapes down-regulati ...... tion and sorting to lysosomes.
@en
prefLabel
EGFRvIII escapes down-regulati ...... tion and sorting to lysosomes.
@en
P2093
P2860
P356
P1433
P1476
EGFRvIII escapes down-regulati ...... tion and sorting to lysosomes.
@en
P2093
Berthe M Willumsen
Bo van Deurs
Hans S Poulsen
Michael V Grandal
Mikkel W Pedersen
P2860
P304
P356
10.1093/CARCIN/BGM058
P407
P50
P577
2007-03-19T00:00:00Z